TSFAE10:	Subjects With Treatment-emergent Related Adverse Events With Frequency =[X]% in [Any Treatment Group] by Preferred Term; Safety Analysis Set (Study jjcs - core)							
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Preferred Term, n (%) 	N=53 	N=73 	N=126 	N=59 	  	  	
DIZZINESS 	4 (7.5%) 	2 (2.7%) 	6 (4.8%) 	0 	7.5 (0.4, 14.7) 	2.7 (-1.0, 6.5) 	
UPPER RESPIRATORY TRACT INFECTION 	0 	0 	0 	3 (5.1%) 	-5.1 (-10.7, 0.5) 	-5.1 (-10.7, 0.5) 	

Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.